A Phase 3 interventional study of primary PCI and enoxaparin in Myocardial Infarction, sponsored by Boehringer Ingelheim. Completed at 201 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-01.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Myocardial Infarction by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Myocardial Infarction · Boehringer Ingelheim.
Among the 12 studies in Myocardial Infarction by Boehringer Ingelheim, this one is the only one that started in 2008, is one of 6 in phase 3, and was the 3rd registered.
2,274 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →None of the 12 studies in Myocardial Infarction by Boehringer Ingelheim is open now. The open studies under Myocardial Infarction, anywhere →
Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,899 is above the median of 150 across 1,315 interventional studies indexed under Myocardial Infarction.
Median enrollment 1,639 across the 8 interventional studies, 206 across the 4 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Myocardial Infarction by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community hospital emergency room without a PCI facility. Following randomisation a strategy of early tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-24 hours with timely coronary intervention as appropriate (or by rescue coronary intervention if required) in Group A will be compared to primary PCI performed according to local standards in Group B.
The study is exploratory in nature and will examine this medical question. The efficacy and safety endpoints as well as mixed (efficacy and safety) composite endpoints up to or before 30 days following randomisation will be evaluated.
All clinical endpoints of main interest will be assessed as single or composite endpoints for evaluation of the trial objective. All statistical tests are of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
4. received
Exclusion criteria:
Medical history, procedures, medication administration or the presence of factors that would in general predispose to bleeding events and/or the inability to evaluate the study primary endpoint
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention
Drug: enoxaparin · Procedure: catheterisation · Drug: tenecteplase · Drug: clopidogrel
Standard primary PCI
Procedure: primary PCI
Standard primary PCI
Adjunctive treatment
Routine or rescue coronary intervention
Single, weight-adjusted i.v. bolus of tenecteplase
Adjunctive treatment
Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.
The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS).
Time frame: 30 days
Number of Patients With All Cause Mortality
This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported.
Time frame: 30 days
Number of Patients With Cardiac Mortality
This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported.
Time frame: 30 days
Number of Patients With Cardiogenic Shock
This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported.
Time frame: 30 days
Number of Patients With Congestive Heart Failure (CHF)
This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported.
Time frame: 30 days
Number of Patients With Recurrent Myocardial Infarction (Reinfarction)
This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported
Time frame: 30 days
Number of Patients With Rehospitalisation for Cardiac Reasons
This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported
Time frame: 30 days
Number of Patients With Rehospitalisation for Non-cardiac Reasons
This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported
Time frame: 30 days
Number of Patients With Serious Repeat Target Vessel Revascularization
This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported
Time frame: 30 days
Number of Patients With All Cause Death and Shock
This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported
Time frame: 30 days
Number of Patients With All Cause Death and Shock and CHF
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported.
Time frame: 30 days
Number of Patients With All Cause Death and Shock and Reinfarction
This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported
Time frame: 30 days
Number of Patients With Total Fatal Stroke
This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported
Time frame: 30 days
Number of Patients With Total Disabling Stroke
This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported
Time frame: 30 days
Number of Patients With Total Non-disabling Stroke
This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported
Time frame: 30 days
Number of Patients With Intracranial Haemorrhage
This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported
Time frame: 30 days
Number of Patients With Ischaemic Stroke
This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported
Time frame: 30 days
Number of Patients With Total Stroke (All Types)
This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported
Time frame: 30 days
Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions
This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported
Time frame: 30 days
Number of Patients With Minor Non-intracranial Bleeds
This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported
Time frame: 30 days
Number of Patients With Total Non-intracranial Bleeds
This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported
Time frame: 30 days
Number of Patients With Serious Resuscitated Ventricular Fibrillation
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported
Time frame: 30 days
Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported
Time frame: 30 days
Number of Patients With All Cause Death and Non-fatal Stroke
This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported
Time frame: 30 days
Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported
Time frame: 30 days
Open-label, prospective, randomised, parallel, comparative international multicentre trial
| Milestone | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Started | 950 | 949 |
| Completed | 949 | 948 |
| Not completed | 1 | 1 |
| Withdrew: Previous enrolment into this study | 1 | 1 |
The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS).
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS. | 116 | 135 |
This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported.
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With All Cause Mortality | 43 | 42 |
This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported.
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Cardiac Mortality | 31 | 32 |
This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported.
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Cardiogenic Shock | 41 | 56 |
This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported.
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Congestive Heart Failure (CHF) | 57 | 72 |
This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Recurrent Myocardial Infarction (Reinfarction) | 23 | 21 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Rehospitalisation for Cardiac Reasons | 45 | 41 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Rehospitalisation for Non-cardiac Reasons | 19 | 11 |
This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Serious Repeat Target Vessel Revascularization | 1 | 2 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With All Cause Death and Shock | 59 | 73 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported.
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With All Cause Death and Shock and CHF | 100 | 123 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With All Cause Death and Shock and Reinfarction | 77 | 85 |
This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Total Fatal Stroke | 7 | 4 |
This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Total Disabling Stroke | 2 | 0 |
This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Total Non-disabling Stroke | 8 | 1 |
This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Intracranial Haemorrhage | 9 | 2 |
This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Ischaemic Stroke | 6 | 3 |
This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Total Stroke (All Types) | 15 | 5 |
This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions | 61 | 45 |
This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Minor Non-intracranial Bleeds | 206 | 191 |
This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Total Non-intracranial Bleeds | 267 | 236 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Serious Resuscitated Ventricular Fibrillation | 32 | 38 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures | 10 | 29 |
This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With All Cause Death and Non-fatal Stroke | 50 | 43 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported
| Participants | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke | 117 | 135 |
Collected over From first drug administration until end of tiral, up to 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tenecteplase (Group A) | 43/949 (4.5%) | 146/949 (15.4%) | 0/949 (0%) |
| Primary PCI (Group B) | 42/948 (4.4%) | 164/948 (17.3%) | 0/948 (0%) |
| Event | Tenecteplase (Group A) | Primary PCI (Group B) |
|---|---|---|
| Ventricular fibrillationCardiac disorders | 41/949 | 46/948 |
| Cardiac arrestCardiac disorders | 10/949 | 16/948 |
| Atrioventricular blockCardiac disorders | 9/949 | 14/948 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 11/949 | 14/948 |
| Ventricular tachycardiaCardiac disorders | 11/949 | 13/948 |
| Atrial fibrillationCardiac disorders | 4/949 | 11/948 |
| PericarditisCardiac disorders | 9/949 | 7/948 |
| Coronary artery occlusionCardiac disorders | 3/949 | 8/948 |
| PneumoniaInfections and infestations | 7/949 | 5/948 |
| Renal failure acuteRenal and urinary disorders | 3/949 | 5/948 |
Full analysis set (FAS): All consented patients either randomised by Interactive Voice Response System (IVRS) or treated (i.e., manually allocated to treatment group) by the investigator. This population is also referred to as the intention-to-treat population (ITT).
| Age, Continuous(Years) | Tenecteplase (Group A) | Primary PCI (Group B) | Total |
|---|---|---|---|
| Mean | 60 ± 12.42 | 60 ± 12.49 | 60 ± 12.46 |
| Sex: Female, Male(Participants) | Tenecteplase (Group A) | Primary PCI (Group B) | Total |
|---|---|---|---|
| Female | 195 | 208 | 403 |
| Male | 754 | 740 | 1494 |
| Race and Ethnicity Not Collected(Participants) | Tenecteplase (Group A) | Primary PCI (Group B) | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
Showing the first 100 of 201 sites across 16 countries. Choose a country and city above to see the rest.
Ran from Mar 2008 to primary completion in Sep 2012, 54 months.
Results were first posted in Aug 2019, 6 years 11 months after primary completion. A results delay was requested in Apr 2014.
Of 57 phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's 54 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenecteplase